David Nierengarten

Stock Analyst at Wedbush

(3.54)
# 841
Out of 4,851 analysts
211
Total ratings
41.86%
Success rate
6.56%
Average return

Stocks Rated by David Nierengarten

Blueprint Medicines
Jun 2, 2025
Downgrades: Neutral
Price Target: $128$129
Current: $128.10
Upside: +0.70%
iTeos Therapeutics
May 28, 2025
Downgrades: Neutral
Price Target: $10$12
Current: $10.20
Upside: +17.65%
Intellia Therapeutics
May 19, 2025
Reiterates: Neutral
Price Target: $10
Current: $7.67
Upside: +30.38%
Nuvation Bio
May 16, 2025
Reiterates: Outperform
Price Target: $5
Current: $2.45
Upside: +104.08%
NovoCure
Apr 16, 2025
Maintains: Neutral
Price Target: $29$27
Current: $16.72
Upside: +61.48%
Kiniksa Pharmaceuticals International,
Apr 16, 2025
Reiterates: Outperform
Price Target: $34
Current: $28.88
Upside: +17.73%
argenx SE
Apr 16, 2025
Reiterates: Outperform
Price Target: $715
Current: $574.30
Upside: +24.50%
Perspective Therapeutics
Mar 27, 2025
Reiterates: Outperform
Price Target: $11
Current: $3.13
Upside: +251.44%
Immunome
Mar 20, 2025
Reiterates: Outperform
Price Target: $33
Current: $9.02
Upside: +265.85%
Sutro Biopharma
Mar 14, 2025
Downgrades: Neutral
Price Target: $8$2
Current: $0.91
Upside: +119.93%
Reiterates: Neutral
Price Target: $5
Current: $1.42
Upside: +252.11%
Reiterates: Outperform
Price Target: $31
Current: $11.16
Upside: +177.78%
Reiterates: Outperform
Price Target: $77
Current: $46.72
Upside: +64.81%
Maintains: Outperform
Price Target: $40
Current: $21.27
Upside: +88.06%
Maintains: Outperform
Price Target: $87$90
Current: $36.50
Upside: +146.58%
Maintains: Outperform
Price Target: $40$47
Current: $30.82
Upside: +52.50%
Reiterates: Outperform
Price Target: $15
Current: $3.98
Upside: +276.88%
Maintains: Outperform
Price Target: $99$115
Current: $76.79
Upside: +49.77%
Reiterates: Outperform
Price Target: $23
Current: $4.96
Upside: +363.71%
Reiterates: Outperform
Price Target: $20
Current: $9.08
Upside: +120.26%
Initiates: Outperform
Price Target: $40
Current: $11.68
Upside: +242.47%
Initiates: Outperform
Price Target: $45
Current: $16.59
Upside: +171.25%
Reiterates: Outperform
Price Target: $10
Current: $1.78
Upside: +461.80%
Initiates: Outperform
Price Target: $18
Current: $1.97
Upside: +813.71%
Reiterates: Outperform
Price Target: $57
Current: $47.32
Upside: +20.46%
Reiterates: Outperform
Price Target: $5
Current: $0.39
Upside: +1,190.66%
Downgrades: Neutral
Price Target: $8$2
Current: $1.34
Upside: +49.25%
Reiterates: Neutral
Price Target: $10
Current: $5.64
Upside: +77.30%
Reiterates: Outperform
Price Target: $11
Current: $0.23
Upside: +4,709.79%
Maintains: Outperform
Price Target: $34$36
Current: $9.10
Upside: +295.60%
Reiterates: Outperform
Price Target: $12
Current: $1.32
Upside: +809.09%
Reiterates: Outperform
Price Target: $57
Current: $17.15
Upside: +232.36%
Upgrades: Outperform
Price Target: $2$7
Current: $0.37
Upside: +1,797.02%
Maintains: Equal-Weight
Price Target: $1,400$500
Current: $3.02
Upside: +16,456.29%
Maintains: Neutral
Price Target: $105$60
Current: $4.34
Upside: +1,282.49%
Maintains: Outperform
Price Target: $11$19
Current: $7.69
Upside: +147.07%
Maintains: Outperform
Price Target: $71$75
Current: $36.57
Upside: +105.09%
Downgrades: Neutral
Price Target: n/a
Current: $1.18
Upside: -
Upgrades: Outperform
Price Target: n/a
Current: $3.32
Upside: -
Downgrades: Neutral
Price Target: n/a
Current: $4.88
Upside: -